Peter Attia· MD
including clinical trials of rapamycin and how dosing strategies, timing, and exercise may influence outcomes.
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
including clinical trials of rapamycin and how dosing strategies, timing, and exercise may influence outcomes.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
The "high risk" framing here is the right call. I've had three patients ask about rapa this month and none of them grasped the immunosuppression tradeoff until I walked them through it.
The PEARL trial framing in the dossier is the clearest writeup I've seen for a non-specialist. Worth linking from the AMA pages too.
I'm on 6mg/week, year two. Tracking IL-6, fasting glucose, lipids. Happy to share the spreadsheet if Whalespan wants longitudinal user data.
The dosing variance across the advocate camp is staggering. 3mg, 5mg, 8mg, biweekly, weekly… brief is right that "monitor or specialist only" is the responsible read.
we should do this with rapamycin dosing like I'm curious as to whether the pulsatile dosing of rapamycin that I take does that have an impact
two of the three treatment arms in that study were only being given rapamycin once a week one at five milligrams one at twenty milligrams
my impression is that the the the the um there has been a movement towards the idea that you know once a week dosing with rapamycin uh is probably better than daily dosing with rapamycin for for aging effects in people and that you know you might want to do it for three months and then you stop for six months and you do it again for three months
even with a drug it's still very complicated to say well what about during this phase because the study i think we were talking about was looking at mice and it was asking the question of early exposure of rapamycin later in life constant dosing intermittent dosing yep that's for a drug and we're still struggling to piece it together
there are some people who are taking you know six milligrams once a week but they're trying to build it up to some higher dose to see where they start to get side effects
so I think our highest was up close to 20 milligrams once a week um again though it was a little bit difficult to tell how long people had been taking rap ay at those doses right so there you know again some people had been taking it I I think our the person who's been taking it the longest was many years like five I don't know about many five or six years so so uh but the majority were 6 months right
and so it's for all of those reasons that I say wow this is really promising but why can I not say this is proven and the reason I can't say it's proven is we don't yet have sufficient evidence in the organ ISM of Interest or the species of Interest which is us and the reason for that is that while there have been some interesting studies done in human and we'll point back to a podcast that I did with um Lloyd clickstein and Joan manic um there are clearly short-term studies that demonstrate that the differential dosing pattern of rapamycin can actually produce immune augmentation and immune enhancement rather than immune suppression that doesn't quite translate to the question that many of us want to know the answer to which is hey if I take Ramy intermittently as demonstrated by these shorter human clinical trials will that translate to not just better um immune function but a longer life
the difference really between these these these two these two world of imunosuppression which clearly has been documented by clinical trials it is imunosuppressive by itself um versus the beneficial effect on the immune system to me is a question of dosage and frequency
Rapamycin extends median and maximum lifespan in mice across multiple lab strains and dosing protocols.
Rapamycin will extend human lifespan by 5+ years at standard weekly dosing.
Weekly rapamycin dosing in healthy adults shows favorable safety and immune markers in early observational data.
Chronic low-dose rapamycin imposes an immune trade-off that outweighs the longevity hypothesis for most healthy adults.
mTORC1 inhibition is the mechanistic backbone for rapamycin's healthspan effects in mammals.
The PEARL trial showed an acceptable 48-week safety profile in healthy adults on weekly rapamycin.